Group items tagged

The Brain Tumor Funders' Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor. To that end, BTFC has issued a Request for Proposals for research on the role of the neuro-immune system in the origin and progression of immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. Priority will be given to studies on immune responses in primary brain tumors in pediatric and/or adult human patients. The program, which will provide grants of up to $250,000 per year over three years, will support a small number of multidisciplinary team-based projects. Teams should represent the requisite skills needed to carry out the proposed research, including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained, including radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma).

Established in 2011 by Granville H. Nickerson, M.D., C.M., in honour and in memory of his wife, Mary Louise, who was an inspiration to many of Dr. Nickerson's classmates of McGill's Medicine Class of 1945, an acknowledged scholar and an enthusiastic promoter of the Arts.  The Fellowship will allow a scholar to carry out research utilizing the Neuro History archival and artifact collections, the centre piece of which is the Penfield Archive in the Osler Library, and other resources available at the Osler Library, the Montreal Neurological Institute and the McGill University Archives.  The Osler Library's collections are listed in the McGill Library Catalogue and the Osler Library Archives Collection website.  

The Brain Tumor Funders' Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor. To that end, BTFC has issued a Request for Proposals for research on the role of the neuro-immune system in the origin and progression of immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. Priority will be given to studies on immune responses in primary brain tumors in pediatric and/or adult human patients. The program, which will provide grants of up to $250,000 per year over three years, will support a small number of multidisciplinary team-based projects. Teams should represent the requisite skills needed to carry out the proposed research, including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained, including radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma).

The Klarman Family Foundation is interested in providing strategic investment in translational research that will accelerate progress in developing effective treatments for anorexia nervosa, bulimia nervosa and binge eating disorder. The Program's short-term goal is to support the most outstanding science and expand the pool of scientists whose research explores the basic biology of feeding, anorexia nervosa, bulimia nervosa, and/or binge eating disorder. The long-term goal is to improve the lives of patients suffering from these conditions. Examples of funding areas include but are not limited to molecular genetic analysis of relevant neural circuit assembly and function; genetic and epigenetic research; animal models created by genetically altering neural circuits; and testing of new chemical entities that might be used in animal models as exploratory treatments.  Please note that imaging studies involving humans are not eligible. Investigators conducting research in the neuro-circuitry of fear conditioning or reward behavior may also apply but must justify the relevance of their research projects to the basic biology of eating disorders. Clinical psychotherapeutic studies, medication trials and research in the medical complications of these disorders are outside the scope of this Program.

The Henrietta B. and Frederick H. Bugher Foundation has joined with the American Stroke Association (ASA, a division of the American Heart Association) to support a network of three Centers of Excellence in Stroke Collaborative Research for a period of four years. The intent of this initiative is to support a collaboration of basic, clinical and population researchers from different specialties whose collective efforts will lead to new approaches, not only to improve the prevention of stroke, but to also expand upon the previous Bugher Stroke initiatives by inviting research on recovery after a stroke; including the areas of repair, regeneration, neuro-plasticity and rehabilitation.   Within the scope of stroke research, scientific disciplines may range from basic to clinical to population with bridges to translational research.  The application must contain at least two of these three disciplines.  Areas of recovery, secondary prevention, nursing, psychology, psychiatry and neuropsychology are strongly encouraged.    A focus has again been placed on fellowship training and cross-center collaboration for this new initiative.  Prospective applicants will be required to illustrate their capability to not only train fellows in stroke research, but also their commitment to collaborate with scientists outside their institution.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

The goal of this initiative is to support the identification, validation and manipulation of neural circuits that underlie cognitive, emotional, and social processes impacted in mental illnesses including alcohol use disorder and other substance abuse. The initiative is focused on probing circuit mechanisms underlying neuro-psychiatrically relevant behavior through studies in non-human primates. This initiative is intended to complement existing institute-funded preclinical investigation of circuits which have often focused on smaller brains.

The "Mechanisms of cellular death in NeuroDegeneration" (MCDN) funding program's overall goal is to discover and understand the mechanisms and pathophysiological processes by which brain cell loss is mediated in disease and thereby seek insights and potential targets for therapeutic interventions that would sustain healthy brain function.

The purpose of this cooperative agreement opportunity is to support the creation and/or maintenance of a transdisciplinary, multisite Research Network that will accelerate the translation of developmental science into MCH practice, promote scientific collaboration, and develop additional research capacity in the fields of adolescent and young adult (ages 10-25) health. A Research Network is a collaboration designed to conduct research across multiple sites, resulting in a greater collective impact. One institution serves as the primary awardee, and oversees and facilitates all Network activities. The Network must include researchers who study adolescence and young adulthood from a range of disciplines, including developmental neuroscience, behavioral and social sciences, and the medical and/or allied health fields, reflecting attention to the health and development of the whole person as well as to health care services for members of these two age groups.

The goal of this FOA is to define and characterize neural cell populations, neural circuits, and brain networks and regions that are vulnerable to brain aging and Alzheimer's disease (AD). Understanding mechanisms underlying selective vulnerability from cells to networks in AD is critical to fully define the disease process and to develop effective therapies. 

The NSF Research Traineeship (NRT) program is designed to encourage the development and implementation of bold, new, and potentially transformative models for STEM graduate education training. The NRT program seeks proposals that ensure that graduate students in research-based master's and doctoral degree programs develop the skills, knowledge, and competencies needed to pursue a range of STEM careers. The NRT program includes two tracks: the Traineeship Track and the Innovations in Graduate Education (IGE) Track.

The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interconnected fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches.

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

This NIA Research Career Enhancement Award (K18) program invites applications from qualified researchers to acquire training and career development experiences that close expertise gaps in data science and in drug discovery. The goal of the program is to allow Alzheimer's Disease (AD) researchers to expand their expertise to become more effective in leading cross-disciplinary, translational, team-science projects in AD or AD-related dementias (ADRD). This award will also allow data scientists to redirect their expertise toward the study of AD and ADRD.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. These awards were established to encourage emerging neuroscientists to focus on disorders of learning and memory. Applicants for the McKnight Scholar Awards must demonstrate interest in solving important problems in relevant areas of neuroscience, including the translation of basic research to clinical neuroscience.

This FOA invites applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias (AD/ADRD).

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure, or treatment of primary brain tumors/brain cancer. The annual award provides up to $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the foundation through its network of scientists in the field and an annual alumni conference.

The purpose of this Funding Opportunity Announcement (FOA) is to advance research on male-females differences in drug and alcohol abuse and addiction and on factors specific to women.  Both human and animal model studies are sought. 

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. . JSPTPN programs are intended to be two years in duration, and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare individuals for careers in neuroscience that will have a significant impact on our understanding of nervous system function and the health-related research needs of the nation.

This Funding Opportunity Announcement (FOA) encourages applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behavior and in substance use and dependence.  All stages of brain development are of interest, but a new emphasis of the current reissue of this initiative is to support basic neuroscience research on fundamental mechanisms of brain development during prepuberty and the adolescent period in relation to the problems of substance abuse and co-morbidity with psychiatric disorders.  Topics of interest pertaining to brain development of this initiative include, but are not limited to, the euphoric properties of abused substances, actions of psychotherapeutic agents, and their consequences on memory, cognitive and emotional processes.  A major goal of this initiative is to understand how exposure to substances of abuse and environmental insults affects the cellular and molecular mechanisms underlying nervous system development and neural circuit functions implicated in substance use and addiction.